LGM
VIGL

Logos Global Management’s Vigil Neuroscience VIGL Stock Holding History

Logos Global Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-188,390
Closed -$1.02M – 72
2023
Q3 		$1.02M Hold
188,390
– – 0.14% 50
2023
Q2 		$1.77M Hold
188,390
– – 0.24% 46
2023
Q1 		$1.84M Hold
188,390
– – 0.26% 38
2022
Q4 		$2.35M Sell
188,390
-17,205
-8% -$211K 0.28% 36
2022
Q3 		$1.87M Hold
205,595
– – 0.23% 31
2022
Q2 		$530K Hold
205,595
– – 0.1% 29
2022
Q1 		$1.45M Buy
+205,595
New +$2.71M 0.19% 38

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Logos Global Management's VIGL Position: Q4 2023 in Review

Logos Global Management sold out of Vigil Neuroscience (VIGL) in Q4 2023, closing a stake of 188,390 shares — an estimated $1.02M sold.

Logos Global Management first reported a position in VIGL in Q1 2022 and held it in 7 quarters. The position peaked at $2.35M in Q4 2022. 46 funds tracked by Wall St. Rank hold VIGL as of Q4 2023.

  • Logos Global Management reported no remaining Vigil Neuroscience position as of Q4 2023 after selling out during the quarter.
  • Logos Global Management sold 188,390 Vigil Neuroscience shares in Q4 2023, an estimated $1.02M.
  • Logos Global Management first reported a position in Vigil Neuroscience in Q1 2022 and held it in 7 quarters.
  • Logos Global Management's Vigil Neuroscience position peaked at $2.35M in Q4 2022.
  • 46 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2023.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.